C12Y 304/24086
Adam 17 endopeptidase , i.e. tnf-alpha converting enyzme
Official title: ADAM 17 endopeptidase (3.4.24.86), i.e. TNF-alpha converting enyzme
C12Y304/24086 (Adam 17 endopeptidase , i.e. tnf-alpha converting enyzme) appears on 12 US grants and 19 published applications in this corpus.
Search patents in C12Y- Granted patents
- 12
- Published applications
- 19
- Assignees
- 12
- Inventors
- 37
- Latest grant
- 6 May 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 1 | 0 |
| 2002 | 0 | 2 |
| 2003 | 2 | 1 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 1 | 0 |
| 2007 | 0 | 1 |
| 2008 | 1 | 0 |
| 2009 | 0 | 2 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 1 |
| 2016 | 0 | 1 |
| 2017 | 1 | 1 |
| 2018 | 0 | 0 |
| 2019 | 1 | 2 |
| 2020 | 1 | 2 |
| 2021 | 1 | 1 |
| 2022 | 0 | 0 |
| 2023 | 1 | 1 |
| 2024 | 0 | 2 |
| 2025 | 1 | 1 |
| 2026 | 0 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compositions and methods for treatment of sepsis-related disorders6 May 2025US 12,290,528 B2
- Compositions and methods for treatment of sepsis-related disorders9 May 2023US 11,642,365 B2
- Variants of TACE pro-domain as TNF-A inhibitor and their medical use2 Mar 2021US 10,933,122 B2Yeda Research and Development Co. Ltd.
- Gene/carrier complex for preventing or treating inflammatory diseases14 Jul 2020US 10,709,793 B2Industry-University Cooperation Foundation Hanyang University
- Variants of TACE pro-domain as TNF-A inhibitor and their medical use1 Oct 2019US 10,426,821 B2Yeda Research and Development Co. Ltd.
- Compositions and methods for the treatment of sepsis13 Aug 2026US 2026/0234635 A1
- Compositions and methods for treatment of sepsis-related disorders17 Jul 2025US 2025/0228886 A1
- Non-viral gene/carrier complex for prevention or treatment of acute inflammatory disease16 May 2024US 2024/0158798 A1Industry-University Cooperation Foundation Hanyang University Erica Campus
- Natural killer cells with enhanced activity11 Jan 2024US 2024/0010980 A1The Regents of the University of California
- Compositions and methods for treatment of sepsis-related disorders14 Sep 2023US 2023/0285440 A1
Most cited
By later US patents
- Mammalian TNF-.alpha. convertases13US 5,853,977 ASchering Corporation · 1998
- Mammalian TNF- α convertase5US 6,531,290 B2Schering Corporation · 2003
- Mammalian TNF-α convertases3US 6,319,681 B1Schering Corporation · 2001
- Mammalian TNF-α convertases2US 7,135,555 B2Schering Corporation · 2006
- Variants of TACE pro-domain as TNF-A inhibitor and their medical use1US 9,764,008 B2Yeda Research and Development Co. Ltd. · 2017